Your session is about to expire
← Back to Search
Pembrolizumab + Radiation Therapy for Multiple Myeloma
Study Summary
This trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are able to carry out light physical activities like walking and taking care of yourself without help.You have myeloma that has come back or hasn't responded to previous treatments, and there's no limit on the number of treatments you've had.You are being considered for radiation therapy by your doctor for your disease, whether or not you have symptoms.You have a single tumor made of plasma cells.You have an ongoing autoimmune disease that needed strong medication in the last 2 years.You have another type of cancer that is getting worse or needs treatment, except for certain types of skin cancer.You have a history of lung inflammation that is not caused by an infection.You have an ongoing infection that needs medicine to treat.You have received treatment with certain drugs that target the PD-1 or PD-L1 proteins in the past.You have asymptomatic multiple myeloma.You have been diagnosed with HIV.You have active hepatitis B or hepatitis C.You have a condition that weakens your immune system.You have a current or past infection with tuberculosis.You are allergic to pembrolizumab or any of the ingredients in it.You have stage I-III multiple myeloma that is getting worse, has come back, or is not responding to treatment.You have at least one bone or tissue growth that can be treated with radiation.Your doctor has determined that you are a suitable candidate for pembrolizumab and your organs are working well.You have received a stem cell transplant from another person.You have a certain level of protein in your urine or blood, or abnormal results from certain tests that show the presence of myeloma.
- Group 1: Radiation therapy, pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What further research has been conducted surrounding Radiation Therapy?
"Currently, there are 961 ongoing medical studies revolving around Radiation Therapy with 122 of them in their final testing phase (phase 3). While many trials take place in Houston, Texas, the total number of clinical trial sites spread across 35731 locations."
To what maladies is Radiation Therapy customarily employed?
"Radiotherapy is generally used to treat malignant tumours, though it can also be helpful for those with unresectable melanoma, high microsatellite instability and disease progression after chemotherapy."
How many individuals have been enrolled in the research project thus far?
"Unfortunately, this research project has concluded its recruitment process. It was originally posted on May 29th 2018 and last updated March 2nd 2022. Nevertheless, there are still 807 trials with multiple myeloma currently recruiting as well as 961 studies concerning Radiation Therapy that you can look into."
Are new participants being accepted for this study?
"At this moment, no further recruitment is underway for the trial that first opened its doors on May 29th 2018. The most recent update was posted on March 2nd 2022. Alternatively, 807 trials are presently searching for patients with multiple myeloma and 961 studies utilizing radiation therapy have open enrolment periods."
Has the FDA authorized Radiation Therapy for use?
"Due to the limited amount of evidence available, radiation therapy is estimated to have a safety score of 1 on our scale. This assessment was made as this experiment is currently in its first phase, with minimal data surrounding both efficacy and security."
Share this study with friends
Copy Link
Messenger